title: An agent-based modeling framework linking inflammation and cancer using evolutionary principles: description of a generative hierarchy for the hallmarks of cancer and developing a bridge between mechanism and epidemiological data.
abstract: Inflammation plays a critical role in the development and progression of cancer, evident in multiple patient populations manifesting increased, non-resolving inflammation, such as inflammatory bowel disease, viral hepatitis and obesity. Given the complexity of both the inflammatory response and the process of oncogenesis, we utilize principles from the field of Translational Systems Biology to bridge the gap between basic mechanistic knowledge and clinical/epidemiologic data by integrating inflammation and oncogenesis within an agent-based model, the Inflammation and Cancer Agent-based Model (ICABM). The ICABM utilizes two previously published and clinically/epidemiologically validated mechanistic models to demonstrate the role of an increased inflammatory milieu on oncogenesis. Development of the ICABM required the creation of a generative hierarchy of the basic hallmarks of cancer to provide a foundation to ground the plethora of molecular and pathway components currently being studied. The ordering schema emphasizes the essential role of a fitness/selection frame shift to sub-organismal evolution as a basic property of cancer, where the generation of genetic instability as a negative effect for multicellular eukaryotic organisms represents the restoration of genetic plasticity used as an adaptive strategy by colonies of prokaryotic unicellular organisms. Simulations with the ICABM demonstrate that inflammation provides a functional environmental context that drives the shift to sub-organismal evolution, where increasingly inflammatory environments led to increasingly damaged genomes in microtumors (tumors below clinical detection size) and cancers. The flexibility of this platform readily facilitates tailoring the ICABM to specific cancers, their associated mechanisms and available epidemiological data. One clinical example of an epidemiological finding that could be investigated with this platform is the increased incidence of triple negative breast cancers in the premenopausal African-American population, which has been identified as having up-regulated of markers of inflammation. The fundamental nature of the ICABM suggests its usefulness as a base platform upon which additional molecular detail could be added as needed.
authors.affiliation: Department of Surgery, University of Chicago, Chicago, IL, United States. Electronic address: docgca@gmail.com.
authors.forename: Gary
authors.initials: G
authors.lastname: An
authors.affiliation: Department of Surgery, University of Chicago, Chicago, IL, United States.
authors.forename: Swati
authors.initials: S
authors.lastname: Kulkarni
mesh_terms: D001741:Black or African American / Q000208:ethnology; D005075:Biological Evolution; D001943:Breast Neoplasms / Q000276:immunology; D063646:Carcinogenesis / Q000276:immunology*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000150:complications*; D009369:Neoplasms / Q000209:etiology*; D017697:Premenopause / Q000276:immunology; D049490:Systems Biology
keywords: Agent-based modeling; Cancer; Computational biology; Evolution; Inflammation; Systems biology
references.citation: Lancet. 2012 Apr 28;379(9826):1602-12
references.pmid: 22440946
references.citation: Math Biosci Eng. 2013 Jun;10(3):787-802
references.pmid: 23906150
references.citation: BMC Syst Biol. 2008 Dec 23;2:110
references.pmid: 19105850
references.citation: PLoS Biol. 2005 Nov;3(11):e392
references.pmid: 16277557
references.citation: Proc Biol Sci. 1992 Jun 22;248(1323):261-71
references.pmid: 1354364
references.citation: Science. 2002 Mar 1;295(5560):1664-9
references.pmid: 11872830
references.citation: J Pharmacokinet Pharmacodyn. 2006 Dec;33(6):737-72
references.pmid: 17051440
references.citation: Nat Rev Cancer. 2013 Nov;13(11):759-71
references.pmid: 24154716
references.citation: Crit Care Med. 2004 Oct;32(10):2050-60
references.pmid: 15483414
references.citation: Am J Hum Genet. 2012 Sep 7;91(3):502-12
references.pmid: 22939635
references.citation: JAMA. 2006 Jun 7;295(21):2492-502
references.pmid: 16757721
references.citation: PLoS Comput Biol. 2008 Apr 25;4(4):e1000014
references.pmid: 18437239
references.citation: Bull Math Biol. 2013 Jan;75(1):161-84
references.pmid: 23196354
references.citation: BMC Syst Biol. 2009 Dec 31;3:122
references.pmid: 20043854
references.citation: Biophys J. 2003 Nov;85(5):2948-61
references.pmid: 14581197
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: Shock. 2001 Oct;16(4):266-73
references.pmid: 11580108
references.citation: Curr Opin Genet Dev. 2010 Feb;20(1):65-71
references.pmid: 20036794
references.citation: Lancet Oncol. 2012 May;13(5):518-27
references.pmid: 22440112
references.citation: PLoS Comput Biol. 2011 Apr;7(4):e1002030
references.pmid: 21490722
references.citation: Annu Rev Immunol. 2012;30:677-706
references.pmid: 22224761
references.citation: Nature. 2002 Dec 19-26;420(6917):846-52
references.pmid: 12490957
references.citation: PLoS One. 2013 May 21;8(5):e64091
references.pmid: 23704974
references.citation: Cancer Res. 2013 Jun 15;73(12):3534-44
references.pmid: 23536560
references.citation: Breast Cancer Res. 2009;11(2):R18
references.pmid: 19320967
references.citation: Carcinogenesis. 2009 Jul;30(7):1073-81
references.pmid: 19468060
references.citation: Pharm Res. 2009 Nov;26(11):2369-400
references.pmid: 19756975
references.citation: J Theor Biol. 2012 Feb 7;294:56-73
references.pmid: 22051568
references.citation: Theor Biol Med Model. 2008 May 27;5:11
references.pmid: 18505587
references.citation: Biol Direct. 2012 Sep 25;7:31
references.pmid: 23009638
references.citation: Cell. 2010 Mar 19;140(6):871-82
references.pmid: 20303877
references.citation: J Theor Biol. 2007 Aug 21;247(4):723-32
references.pmid: 17543345
references.citation: Cell. 2000 Jan 7;100(1):57-70
references.pmid: 10647931
references.citation: Proc Natl Acad Sci U S A. 2011 Sep 13;108 Suppl 3:15624-30
references.pmid: 21788505
references.citation: Cell. 2010 Mar 19;140(6):883-99
references.pmid: 20303878
references.citation: Theor Biol Med Model. 2012 Jul 28;9:31
references.pmid: 22838395
references.citation: Interface Focus. 2013 Aug 6;3(4):20130010
references.pmid: 24511375
references.citation: J Clin Invest. 2008 Jun;118(6):1991-2001
references.pmid: 18523649